Ribokis is identified on this website as a product containing 200 mg of ribociclib. Product-specific manufacturer and authorization information requires verification.

Ribociclib is an oral CDK4/6 inhibitor used with endocrine therapy for specified HR-positive/HER2-negative breast cancers.

Current U.S. labeling includes selected HR-positive/HER2-negative stage II and III early breast cancer and advanced or metastatic breast cancer indications.

Ribociclib inhibits CDK4 and CDK6, helping interfere with cell-cycle progression.

The Ribokis product is identified for this website as 200 mg. The current U.S. KISQALI reference product is also supplied as 200 mg tablets.

Current U.S. regimens use once-daily administration for 21 consecutive days followed by 7 days off in a 28-day cycle. The starting dose depends on the indication.

Yes. Current U.S. labeling allows ribociclib to be taken with or without food.

Current U.S. labeling states that no additional dose should be taken that day after a missed dose; the next prescribed dose should be taken at the usual time.

Common reactions vary by treatment setting but can include blood-count abnormalities, liver-enzyme elevations, infections, nausea, fatigue, headache and other gastrointestinal or constitutional symptoms.

Yes. Neutropenia is a recognized and clinically important adverse reaction. CBC monitoring is required under the prescribing information.

Yes. Hepatotoxicity and elevations in liver enzymes can occur, and liver-function monitoring is required.

Yes. Ribociclib can prolong the QT interval. ECG and electrolyte monitoring are part of the safety management, and medicines known to prolong QT should generally be avoided.

Ribociclib can cause ILD or pneumonitis, including severe or fatal cases. New or worsening respiratory symptoms require clinical assessment.

Yes. Severe cutaneous adverse reactions, including SJS, TEN and DRESS, have been reported.

KISQALI is the established branded ribociclib medicine.

KISQALI was developed by Novartis under a research collaboration with Astex Pharmaceuticals.

This should not be assumed solely because both products contain ribociclib. The specific manufacturer, formulation, authorization and product documentation should be compared.

Yes. Depending on the regimen, monitoring includes CBCs, liver-function tests, ECGs and electrolytes.

Yes. Important interactions involve strong CYP3A inhibitors, strong CYP3A inducers, CYP3A substrates and medicines that prolong the QT interval.

Ribociclib can cause embryo-fetal toxicity. Pregnancy-related risks should be discussed with a qualified healthcare professional.

Current U.S. labeling advises against breastfeeding during KISQALI treatment.

Yes. Dose interruption and reduction are included in the prescribing information for management of certain toxicities.